← Back
Data updated: Mar 29, 2026
ZYDUS LIFESCIENCES
CardiovascularDermatologyImmunology
Generics
ZYDUS LIFESCIENCES is a generic drug manufacturer focused on Cardiovascular, Dermatology, Immunology. Key products include ZITUVIO.
2005
Since
89
Drugs
-
Trials
861
Approved (2yr)
Key Drugs
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)
doxorubicin hydrochloride
DNA 10 indications · 2013
ZITUVIMET XR
metformin hydrochloride
1 indications · 2024
ZITUVIMET
metformin hydrochloride
DPP-4 1 indications · 2023
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE
candesartan cilexetil
AT1 receptor 1 indications · 2012
JAYTHARI
deflazacort
Glucocorticoid receptor 1 indications · 2025
Top Drug Revenues Pro
Loading...
Revenue Over Time Pro
Loading...
Recent Activity
DILTIAZEM HYDROCHLORIDE 2026-02-23
Labeling
DILTIAZEM HYDROCHLORIDE 2026-02-23
Labeling
EFINACONAZOLE 2026-02-23
DOXYCYCLINE HYCLATE 2026-02-19
METRONIDAZOLE 2026-02-17
Labeling
METRONIDAZOLE 2026-02-17
Labeling
METRONIDAZOLE 2026-02-13
AMMONIUM LACTATE 2026-02-12
SEC Filings
Pro
Loading...
Therapeutic Areas
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Cardiovascular 32%
8 drugs
Dermatology 20%
5 drugs
Immunology 17%
4 drugs Phase 2: 1
Respiratory 16%
4 drugs
Metabolic 16%
4 drugs
Pipeline Forecast
Loading...
Loading...
Upcoming Trial Milestones Pro
Loading...
Patent Cliff Pro
Loading...
Loading...
Loading...
Competitors by Therapeutic Area
AstraZeneca big-pharma
Respiratory, Cardiovascular, Metabolic, Immunology
Novartis big-pharma
Cardiovascular, Immunology, Respiratory
Boehringer Ingelheim big-pharma
Metabolic, Respiratory, Immunology, Cardiovascular
Merck big-pharma
Cardiovascular, Immunology, Metabolic
PHARMACIA AND UPJOHN big-pharma
Dermatology, Respiratory, Immunology, Metabolic
Active (53)
JAYTHARI ZITUVIMET XR DEFLAZACORT METHYLENE BLUE ZITUVIMET ZITUVIO MACITENTAN TAVABOROLE ICOSAPENT ETHYL DARUNAVIR VIGABATRIN IVERMECTIN OMEGA-3-ACID ETHYL ESTERS CANDESARTAN CILEXETIL DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE VALSARTAN AND HYDROCHLOROTHIAZIDE ZIPRASIDONE HYDROCHLORIDE FELBAMATE BALSALAZIDE DISODIUM VALACYCLOVIR HYDROCHLORIDE SERTRALINE HYDROCHLORIDE AZITHROMYCIN LEFLUNOMIDE BENAZEPRIL HYDROCHLORIDE MIDODRINE HYDROCHLORIDE METHENAMINE HIPPURATE AMMONIUM LACTATE FLUDROCORTISONE ACETATE BISOPROLOL FUMARATE PROPAFENONE HYDROCHLORIDE URSODIOL KETOCONAZOLE DESOXIMETASONE KETOROLAC TROMETHAMINE ACYCLOVIR PROCHLORPERAZINE MALEATE DICLOFENAC SODIUM LOPERAMIDE HYDROCHLORIDE BACLOFEN CLINDAMYCIN PHOSPHATE CYCLOPHOSPHAMIDE BETAMETHASONE DIPROPIONATE VERAPAMIL HYDROCHLORIDE DAPSONE NYSTATIN PHYTONADIONE ACETAZOLAMIDE DOXYCYCLINE HYCLATE FLUOCINONIDE ERYTHROMYCIN DOXEPIN HYDROCHLORIDE DEXAMETHASONE
Discontinued (34)
EFINACONAZOLE DILTIAZEM HYDROCHLORIDE METRONIDAZOLE TRETINOIN PRUCALOPRIDE SUCCINATE CHLORPROMAZINE HYDROCHLORIDE ROPINIROLE HYDROCHLORIDE MECLIZINE HYDROCHLORIDE SUCRALFATE VALBENAZINE TOSYLATE CLOBETASOL PROPIONATE FLUPHENAZINE HYDROCHLORIDE METFORMIN HYDROCHLORIDE ESCITALOPRAM OXALATE FEBUXOSTAT PIROXICAM CLOPIDOGREL BISULFATE MEMANTINE HYDROCHLORIDE DUTASTERIDE LIOTHYRONINE SODIUM INDOMETHACIN IBUPROFEN AND FAMOTIDINE THEOPHYLLINE VALSARTAN ZONISAMIDE DONEPEZIL HYDROCHLORIDE FINASTERIDE AND TADALAFIL IBRUTINIB ISOSORBIDE DINITRATE LIDOCAINE AND PRILOCAINE LEVOFLOXACIN NORTRIPTYLINE HYDROCHLORIDE SELEXIPAG NYSTATIN AND TRIAMCINOLONE ACETONIDE
Company Info
- First Approval
- 2005-04-20
- Latest
- 2026-02-13
- Applications
- 102